Secretogranin II, an acidic protein in the chromogranin/secretogranin family, is widely distributed in neuroendocrine secretory granules. What factors govern such widespread, yet selective, expression? The 5Ј deletions localized neuroendocrine cell type-specific expression to the proximal mouse secretogranin II promoter: such expression was abolished after deletion past the cAMP response element (CRE; [Ϫ67 bp]TGACGTCA[Ϫ60 bp]), and transfer of the CRE to a neutral promoter conferred 3.4-to 5.3-fold neuroendocrine selectivity. Thus, the CRE is, at least partly, sufficient to confer tissue-specific expression. Substantial (48 -59%) loss of cell type-specific expression also occurred upon deletion past the serum response element (SRE; [Ϫ302 bp]GATGTCC[Ϫ296 bp]), and transfer of the SRE to a neutral promoter also conferred neuroendocrine selectivity. Expression of both the endogenous gene and the transfected secretogranin II promoter was up-regulated after secretagogues, and the degree of trans-activation of the transfected promoter (2.2-to 5.4-fold) paralleled activation of the endogenous gene (1.8-to 3.2-fold). The 5Ј promoter deletions revealed complete loss of secretagogue responses after deletion past the CRE. Transfer of the CRE to a neutral promoter conferred secretagogue responses (by 2.2-to 18.6-fold). Substantial (59 -74%) falls in secretagogue responses also occurred after deletion past the promoter's SRE. Transfer of the SRE to a neutral promoter conferred secretagogue responses (by 2.7-to 8.3-fold). We conclude that the CRE is a crucial determinant of cell type-specific constitutive and secretagogue-inducible expression of the secretogranin II gene and that the SRE also plays a substantial role in both processes. (Endocrinology 140: 739 -749, 1999) S ECRETOGRANIN II, a member of the chromogranin/ secretogranin secretory protein family, was initially discovered in the anterior pituitary (1). Later, secretogranin II messenger RNA (mRNA) and protein were found to be widely distributed in endocrine and neuroendocrine cells, as well as in brain (2-4). Secretogranin II is an excellent marker for the regulated secretory pathway (5, 6), a useful histological tumor marker for a variety of neoplasms arising from endocrine and neuroendocrine cells (3, 7, 8) , and the precursor of the biologically active peptide secretoneurin (9), which induces dopamine release (10) in the striatum of rat brain and exerts chemotactic activity toward monocytes (11).
the endogenous gene and the transfected secretogranin II promoter was up-regulated after secretagogues, and the degree of trans-activation of the transfected promoter (2.2-to 5.4-fold) paralleled activation of the endogenous gene (1.8-to 3.2-fold). The 5Ј promoter deletions revealed complete loss of secretagogue responses after deletion past the CRE. Transfer of the CRE to a neutral promoter conferred secretagogue responses (by 2.2-to 18.6-fold). Substantial (59 -74%) falls in secretagogue responses also occurred after deletion past the promoter's SRE. Transfer of the SRE to a neutral promoter conferred secretagogue responses (by 2.7-to 8.3-fold). We conclude that the CRE is a crucial determinant of cell type-specific constitutive and secretagogue-inducible expression of the secretogranin II gene and that the SRE also plays a substantial role in both processes. (Endocrinology 140: 739 -749, 1999) S ECRETOGRANIN II, a member of the chromogranin/ secretogranin secretory protein family, was initially discovered in the anterior pituitary (1) . Later, secretogranin II messenger RNA (mRNA) and protein were found to be widely distributed in endocrine and neuroendocrine cells, as well as in brain (2) (3) (4) . Secretogranin II is an excellent marker for the regulated secretory pathway (5, 6) , a useful histological tumor marker for a variety of neoplasms arising from endocrine and neuroendocrine cells (3, 7, 8) , and the precursor of the biologically active peptide secretoneurin (9) , which induces dopamine release (10) in the striatum of rat brain and exerts chemotactic activity toward monocytes (11) .
Secretogranin II mRNA levels are selectively elevated in the paraventricular nuclei of the hypothalamus by salt-loading (12, 13) , after adrenalectomy and during lactation (14) , or in other brain regions after treatment with kainic acid (15) , reserpine (16) , or the neurotoxin ethylcholine aziridinium (17) . Other studies have shown that secretogranin II gene expression is elevated in the rat adrenal medulla after reserpine (18) ; in rat pheochromocytoma PC12 cells after nerve growth factor (NGF) (19) and after depolarization (20) ; in primary cultures of bovine chromaffin cells after forskolin (21) or histamine (22) , nicotine, or prostaglandin (23) ; and in rat neurons after forskolin or phorbol ester [phorbol-12-myristate-13-acetate (PMA) (24) ].
The secretogranin II gene (Scg2) has been isolated from both mouse (25) and rat (26) , and the Scg2 locus has been positioned to human chromosome 2q35-q36, mouse chromosome 1, and rat chromosome 9 (27) . The secretogranin II protein is entirely encoded by one exon (exon 2) (25) . This distinguishes the genomic organization of secretogranin II gene from that of the other two classical members of the chromogranin family, chromogranin B [5 exons (28) ] and chromogranin A [8 exons (29 -31) ]. The secretogranin II gene contains a cAMP response element [CRE: TGACGTCA (25) ], which seems to be functional (32) . In addition, the secretogranin II promoter is unique in the chromogranin/secretogranin protein family, in having a sequence motif compatible with a serum response element (SRE: GATGTCC) (25, 26) .
What factors govern the activity of the secretogranin II gene, to yield such a widespread (yet neuroendocrine-selective) pattern of expression? The chromogranin/secretogranin proteins each have widespread neuroendocrine expression (3, 7) . Comparison of the mouse chromogranin A, chromogranin B, and secretogranin II promoters reveals only two features in common: CREs 67 to 102 bp upstream of the cap sites, and TATA boxes 22 to 31 bp upstream of the cap sites (25, 28, 29) . For chromogranin A, the CRE seems to be the crucial element in conferring cell-type specificity of expression, in both the mouse (33) and human (34) genes, although other elements may also be important (35) . The chromogranin A CRE also seems to confer response to a variety of secretagogues, including cAMP (33), nicotinic cholinergic agonists (36, 37) , NGF (38) , and neuropeptides (39) . Both CRE and SRE motifs occur in the secretogranin II promoter (25) . Although the secretogranin II CRE is functional (32) , cAMP-induced transcription was not uniform in all cell types, and no data exist on the function of the secretogranin II SRE.
To gain insight into the molecular basis for neuroendocrine cell type-specific expression of secretogranin II, we characterized the mouse secretogranin II gene promoter (to Ϫ4.5 kb upstream of the cap site [ϩ1]) and found that the CRE, at [Ϫ67 bp] TGACGTCA [Ϫ60 bp], plays an indispensable role in neuroendocrine cell type-specific expression of the gene. The SRE region, at [Ϫ302 bp] GATGTCC [Ϫ296 bp], also played a role in such expression. We then extended our studies to explore whether the CRE or SRE are important for inducible expression, and we found that activation of secretogranin II gene expression by cAMP, nicotinic cholinergic, peptidergic, or trophic stimulation is indeed mediated largely via the CRE box, with an additional substantial role for the SRE.
Materials and Methods

Sequencing of the mouse secretogranin II promoter
A 6.3-kb EcoRI-fragment containing the 5Ј upstream region of the secretogranin II gene (25) was sequenced. Double-stranded DNA sequencing was performed by the automated fluorescent sequencing method, using oligonucleotide primers either to vector sequences or to mouse genomic secretogranin II sequences. Eight microliters of Prism Dye-terminator Ready Reaction Mix from PE Applied Biosystems (ABI)/Perkin-Elmer Corp. (Foster City, CA), which contains buffer, nucleotides, dye-terminators, and a specially modified FS AmpliTaq polymerase, was added to 500 ng DNA template plus 3.2 pmol of primers. Amplification was done on an MJ Research, Inc. DNA Engine PTC200 (MJ Research, Inc., Waltham, MA), with Hot Start at 96 C. Then 25 cycles were run at: 96 C for 10 sec, 52 C for 5 sec, and 60 C for 4 min. The samples were then purified on Pharmacia G50 Microspin Sepharose Columns (Pharmacia, Piscataway, NJ) to get rid of excess dye-nucleotides and were lyophilized in a Speedvac for 30 min. Three microliters of a formamide and a blue dextran dye (5:1 ratio) solution was added to the pellet, vortexed, heated to 96 -100 C to get rid of secondary structures, and then quick-chilled. The samples were then loaded on a 6% polyacrylamide gel (Bio-Rad Laboratories, Inc., Hercules, CA) for 12 h at 30 watts on an ABI 373A autosequencer. The data were collected and analyzed by the ABI 2.1.1 software.
Construction of a series of secretogranin II 5Ј promoter deletion/luciferase reporter plasmids for transfection
The fragment (approximately 6.3 kb), containing approximately 4.5 kb promoter sequence (25), exon 1 ending approximately 100 bp in front of HindIII site, and approximately 1.8 kb of the intron, was subcloned into the EcoRI site of the pBluescript II KS Ϯ vector (Stratagene, La Jolla, CA). This promoter plasmid (⌬EcoRI) was used for subsequent subcloning of fragments into the pXP1 luciferase vector (40) .
The following series of 5Ј promoter deletion/luciferase reporter plasmids was constructed. pXPC4500 (Ϫ4500 bp to ϩ8 bp). The ⌬EcoRI construct was digested with SmaI and KpnI. The pXPC1494 construct (see below) was digested with XhoI plus KpnI. The XhoI terminus was filled with Klenow fragment and then ligated to the SmaI-KpnI fragment. This construct was named pXPC4500. pXPC40 (Ϫ40 bp to ϩ8 bp). pXPC982 was digested with BglII plus NarI. The 5Ј-overhangs were filled in with Klenow fragment, and the blunt ends were ligated.
Creation of pTK-SgII-CRE-Luc and pTK-SgII-⌬CRE-Luc promoter/luciferase reporter plasmids
A single copy of a double-stranded oligonucleotide CRE (GGTCCT-GACGTCATTTCC; CRE box in bold) fragment was inserted into the polylinker immediately upstream of the heterologous herpes simplex virus thymidine kinase (TK) promoter in the luciferase reporter vector pTK-Luc (40); the resulting plasmid was called pTK-SgII-CRE-Luc. A similar construction was made with a point-mutated SgII CRE (TGA-GTAA; two point mutations shown in bold and underlined), and the plasmid was called pTK-SgII-⌬CRE-Luc. . The SRE-Luc construct was created by ligating human c-Fos SRE-containing 28 bp oligonucleotide duplexes (ACAGGATGTCCATATTAGGACATCTGCG; SRE in bold) directly upstream from a truncated mouse c-Fos promoter (Ϫ56 bp to ϩ109 bp), which was, in turn, fused to a luciferase reporter in the vector pSVO-Luc (41) . The c-Fos SRE plasmid thus contains both a TATA box and a SRE in its promoter. The ⌬SRE-Luc plasmid has the same mouse c-Fos promoter (Ϫ56 bp to ϩ109 bp) fused to a luciferase reporter but lacks the SRE (41) .
Cell culture and transfections
Early passage number (passage 12-25) PC12 rat pheochromocytoma cells (42) were obtained from David Schubert, Ph.D., Salk Institute, La Jolla, CA. They were cultured in high-glucose DMEM with 10% heatinactivated horse serum, 5% heat-inactivated FBS, and 1% penicillin/ streptomycin (100% stocks were 10,000 U/ml penicillin G and 10,000 g/ml streptomycin sulfate; Life Technologies, Inc., Gaithersburg, MD). The mouse gonadotrope cell line (␣T3-1) (43) and mouse hypothalamic neuronal cell line (GT1-7) (44, 45) were obtained from Pamela L. Mellon (University of California, San Diego). The ␣T3-1 cell line was created by targeted tumorigenesis in transgenic mice using the regulatory region from the human pituitary glycoprotein hormone ␣-subunit gene, and thus represents a cell from the gonadotrope lineage of the pituitary (43) . The GT1-7 cell line was generated by targeted tumorigenesis in trans-genic mice using the 5Ј-flanking region of the GnRH gene coupled to the coding region for the SV40 large T antigen and represents immortal, differentiated hypothalamic neurons (44, 45) . These cells were cultured in high-glucose DMEM with 10% heat-inactivated FBS, and 1% penicillin/streptomycin. The mouse anterior pituitary corticotrope cell line AtT20 (46) was obtained from M. G. Rosenfeld's laboratory (University of California, San Diego) and cultured in high-glucose DMEM with 10% heat-inactivated FBS, and 1% penicillin/streptomycin. The NIH-3T3 (nonneuroendocrine, control) fibroblast cell line was obtained from ATCC(American Type Culture Collection, Rockville, MD) and grown in high-glucose DMEM with 10% heat-inactivated FCS, and 1% penicillin/ streptomycin. The rat somatotrope GC cell line (47) was obtained from Michael Karin's laboratory (University of California, San Diego) and was grown in DME/F12 with 10% heat-inactivated FBS, and 1% penicillin/ streptomycin. Cath-a [CNS TH (tyrosine hydroxylase-expressing] and Path-2 (adrenal TH-expressing) cell lines were obtained from Dona Chikaraishi (Tufts University School of Medicine, Boston, MA). The Cath-a cell line was derived from a TH-expressing brain stem tumor in a transgenic mouse carrying the SV40 T antigen under the transcriptional control of the rat TH 5Ј-flanking DNA (48) . A similar approach was used (48) to obtain the Path-2 (peripheral nervous system TH expressing) cell line from an adrenal tumor. Cos-1 cells (SV40 T antigentransformed kidney fibroblast cell line) and 293 cells (human adenovirus 5 transformed kidney epithelial cell line) were obtained from the ATCC.
Supercoiled plasmid DNA for transfection was grown in Escherichia coli strain DH-5␣ and purified on columns (Qiagen Inc., Chatsworth, CA). One day before transfection, cells were split onto poly-d-lysine (Sigma Chemical Co., St. Louis, MO) coated 6-cm plastic plates, at 40 -50% cell confluence. Cells were transfected with 2.5 g of supercoiled luciferase reporter plasmid DNA per plate, using either the lipofection method (49) (Lipofectamine; Gibco BRL, Bethesda, MD) or the polycationic method (Superfect reagent, Qiagen Inc.). Cells were harvested 30 -36 h after transfection for constitutive expression. For inducible expression, cells were harvested 16 -24 h after treatment. Cell extracts were prepared and assayed for protein (50) , luciferase (51) , and chloramphenicol acetyltransferase (CAT) (52) . To control for differences in transfection efficiency between plasmids, transfections were accompanied by cotransfection of another reporter plasmid, pRSV-CAT (52), expressing the CAT reporter driven by the strong Rous sarcoma virus (RSV) promoter.
Northern blot analysis of mRNA
Total RNA was isolated from cells by guanidinium thiocyanate extraction (RNAzolB; Tel-Test, Friendswood, TX). RNAs (10 -20 g) were size-fractionated on denaturing 1% agarose-formaldehyde gels, transferred to nitrocellulose membranes, and fixed with UV irradiation (StrataLinker; Stratagene). The integrity of the RNA was judged by the appearance of 28S and 18S ribosomal RNA (rRNA) bands on the ethidium bromide-stained gel. The blots were prehybridized, hybridized, and washed as described (33) .
Random primer-labeled (53) cDNA probes were: a 1.8-kb rat secretogranin II cDNA (54) and a 381-bp mouse cyclophilin cDNA (55), used as a normalizing probe for a housekeeping (constitutively expressed) mRNA. Expression of mRNAs was quantified using a StrataScan 7000 densitometer (Stratagene), and normalized to cyclophilin gene expression.
Chemicals
Nicotine, forskolin, and dibutyryl-cAMP were obtained from Sigma Chemical Co. Synthetic (pituitary adenylyl cyclase activating polypeptide) PACAP-38 was obtained from Peninsula Laboratories, Inc. (Belmont, CA). NGF (2.5S, murine, natural) and basic fibroblast growth factor (bFGF) (human, recombinant) were from Life Technologies (Gibco BRL).
Data presentation and analysis
Secretagogue potency was estimated as the EC 50 (concentration required to give half-maximal effect) value, using the program Kaleidagraph (Synergy/Abelbeck Software, Reading, PA). We chose secretagogue doses based on 10-fold (log 10 ) dose-response curves for each agent, and then we conducted subsequent studies at submaximal doses that were at or above the EC 50 values for each drug. Transfection experiments were repeated at least three times, with three plates per condition in each experiment. Results are expressed as the mean value Ϯ 1 sem. Descriptive and inferential statistics were performed with the program InStat (GraphPad Software, Inc., San Diego, CA). Student's t tests or ANOVAs were used, as appropriate. Significance was determined at the P Յ 0.05 level. 
Results
Sequence of the mouse secretogranin II promoter
Sequence analysis (Fig. 1) (Fig. 1) .
Comparison of the first 1345 bp of rat (26) and mouse (present work) secretogranin II promoters revealed a 1138/1345 ϭ 85% homology; beyond 1345 bp, the sequence diverged substantially. The TATA box, CRE, and SRE sequences (as described above) were entirely conserved in the rat and mouse genes.
The endogenous secretogranin II gene in neuroendocrine cells
Basal expression. We investigated the expression of the endogenous secretogranin II gene by Northern blot in clonal cell lines. A high level of steady-state secretogranin II mRNA was observed in adrenomedullary [Path-2 ( Fig. 2 ) and PC12 pheochromocytoma ( Fig. 3) ], pituitary [AtT20 corticotrope, ␣T3-1 gonadotrope, and GC somatotrope ( Fig. 2) ], and neuronal [Cath-a ( Fig. 2 ) and GT1-7 ( Fig. 4) ] cell lines, though not in control (nonneuroendocrine, NIH-3T3) cells (Fig. 2) .
Inducible expression. Because acetylcholine is the physiological stimulus for chromaffin cell secretion (56) of catecholamines and costored proteins, including secretogranin II, we investigated whether nicotine can stimulate expression of the secretogranin II gene. Nicotine (100 m, 24 h) augmented expression of the secretogranin II gene by 1.8-fold (Fig. 3) .
Because the secretogranin II promoter contains a CRE box (Fig. 1 ), reported to be functional (32), we tested its regulation by stimulants of the protein kinase A (PKA) pathway (e.g. the adenylyl cyclase activator forskolin, or the PKA activator cAMP). Forskolin (10 m, 24 h) activated expression of the secretogranin II gene in pituitary (␣T3-1) or neuronal (GT1-7) cell lines by 3.2-or 1.8-fold, respectively (Fig. 4) , whereas dibutyryl cAMP (0.5 mm, 24 h) activated secretogranin II in adrenomedullary (PC12 pheochromocytoma) cells by 1.9-fold (Fig. 3) . Northern blot results were confirmed in a second set of independent experiments.
The SRE may mediate responses to several growth factors (57, 58) . Because the secretogranin II gene contains a SRE (Fig.  1) , we tested the effects of NGF or bFGF in PC12 cells, and found a 2.3-fold increases in secretogranin II mRNA after either treatment (Fig. 3) .
Expression of the transfected secretogranin II promoter: 5Ј promoter deletion mutants
The 4.5-kb promoter conferred expression in neuroendocrine cells, including cell lines of the adrenal medulla (rat PC12 and mouse Path-2 cells) (Fig. 5A) , pituitary (AtT20, GC, and ␣T3-1) (Fig. 5B) , and brain (GT1-7 and Cath-a) (Fig. 5C ) but not in control (nonneuroendocrine) cells, such as NIH-3T3 fibroblasts (Fig. 5, A-D) , 293 epithelial cells (Fig. 5D ), or Cos-1 fibroblasts (Fig. 5D) . Expression in neuroendocrine (62-75% loss of activity) when cells were transfected with the secretogranin II CRE point mutant (Fig. 6A) .
(b) Role of the SRE domain. PC12, AtT20, or NIH-3T3 (control) cells were transfected with c-Fos-SRE-Luc (wild-type SRE) or c-Fos-⌬SRE-Luc (lacking an SRE). c-Fos-SRE-Luc demonstrated substantial neuroendocrine selectivity of expression, with 6.1-to 9.8-fold more expression in PC12 or AtT20 cells than in NIH-3T3 cells (Fig. 6B) . Removal of the SRE (in c-Fos-⌬SRE-Luc) resulted in over 90% loss of neuroendocrine selectivity of expression (Fig. 6B) .
Inducible expression of the secretogranin II promoter: search for cis elements mediating inducibility.
cAMP. The transfected secretogranin II promoter displayed 3-fold cAMP inducibility in neuroendocrine PC12 cells (Fig.  7A) , and no inducibility was seen in nonneuroendocrine NIH-3T3 cells (Fig. 7B) . The cAMP inducibility in PC12 cells was preserved until 5Ј deletions passed Ϫ76 bp, removing the CRE at [Ϫ67 bp] TGACGTCA [Ϫ60 bp]. All promoter deletion mutants downstream (3Ј) of the CRE failed to respond to cAMP.
Nicotinic cholinergic stimulation.
In bovine chromaffin cells, nicotine activates the secretogranin II gene (21, 23) . In PC12 cells, we found a 2.3-fold increase in secretogranin II transfected promoter activity in PC12 cells after nicotine (Fig. 8A ), compared with a 1.8-fold induction of the endogenous secretogranin II gene (Fig. 3) . During serial 5Ј deletions, the nicotine response was retained up to Ϫ76 bp, but entirely lost at Ϫ40 bp (Fig. 8A) , implicating the CRE at [Ϫ67 bp] TGACGTCA [Ϫ60 bp]. To determine whether the CRE is sufficient to confer a nicotine response, we transfected PC12 cells with pTK-SgII-CRE-Luc (wild-type secretogranin II CRE) or pTK-SgII-⌬CRE-Luc (CRE point mutant). The CRE domain conferred a 2.3-fold increment in nicotine response onto the heterologous TK promoter, but a 74% fall in this nicotine response occurred if the CRE was point-mutated (Fig. 8B) .
What was the role of the SRE domain in the nicotine response? A 74% fall in the nicotinic inducibility occurred in the Ϫ76 bp promoter, compared with the Ϫ331 bp promoter (Fig. 8A) . This region contains the SRE, at [Ϫ302 bp] GATGTCC [Ϫ296 bp]. To discern whether the SRE is sufficient to confer a nicotine response, we transfected PC12 cells with c-Fos-SRELuc (wild-type SRE) or c-Fos-⌬SRE-Luc (lacking an SRE). The c-Fos SRE conferred a nicotine response (by 2.7-fold), but a c-Fos promoter lacking an SRE failed to respond to nicotine (Fig. 8C) .
PACAP. In addition to the classic preganglionic neurotransmitter acetylcholine, noncholinergic transmitters (such as PACAP) may stimulate catecholamine secretion and biosynthetic enzyme transcription in adrenal medullary chromaffin cells (39, 59 -62) . In PC12 cells (Fig. 8A) , PACAP stimulated the transfected secretogranin II promoter 5.4-fold. During 5Ј promoter deletions, the PACAP response was retained up to Ϫ76 bp but was entirely lost by Ϫ40 bp (Fig. 8A) . This region contains the CRE. To discern whether the CRE is sufficient to confer a PACAP response, we transfected PC12 cells with pTK-SgII-CRE-Luc (wild-type secretogranin II CRE) or pTKSgII-⌬CRE-Luc (CRE point mutant). The wild-type CRE conferred an 18.6-fold increment in PACAP response onto the heterologous TK promoter, but a 63% loss of the PACAP response was noted for the CRE point mutant (Fig. 8B) .
Upon 5Ј secretogranin II promoter deletion past the SRE, 61% of the PACAP response was lost (Fig. 8A) . To determine whether the SRE is sufficient to confer a PACAP response, we transfected PC12 cells with c-Fos-SRE-Luc (wild-type SRE) or c-Fos-⌬SRE-Luc (lacking the SRE). The c-Fos SRE conferred an 8.3-fold increment in PACAP response, but a 97% loss of FIG. 8. Effects of nicotine or PACAP on the activity of secretogranin II promoter. A, Secretogranin II promoter expression in response to nicotine (500 M) or PACAP-38 (100 nM). Secretogranin II promoter progressive 5Ј deletion mutant/luciferase reporter plasmids were transfected, along with the transfection control efficiency plasmid, pRSV-CAT. Transfected cells were treated with either vehicle (control) or secretagogue for 24 h. Results are expressed as ratios of luciferase/CAT activities (n ϭ 6 transfections for each plasmid). *, P Ͻ 0.0003. B, Stimulation of a heterologous TK promoter by the secretogranin II CRE site in response to nicotine (500 M) or PACAP-38 (100 nM). After transfection with synthetic CRE-TK-luciferase constructs, PC12 cells were treated with nicotine (500 M) or PACAP-38 (100 nM) for 24 h. Luciferase results were normalized to CAT activity (n ϭ 6 transfections for each plasmid). Secretogranin II CRE point mutations are indicated in bold and underlined type. *, P Ͻ 0.0001. C, Role of the SRE in inducible gene expression in PC12 cells in response to nicotine (500 M) or PACAP38 (100 nM). Synthetic c-Fos-SRE-luciferase constructs were transfected into PC12 cells, which were treated with nicotine (500 M) or PACAP-38 (100 nM) for 24 h. Luciferase results were normalized to CAT activity (n ϭ 6 transfections for each plasmid). *, P Ͻ 0.0001.
that PACAP response was noted in the c-Fos promoter lacking an SRE (Fig. 8C) .
Growth factors. NGF is known to augment expression of the secretogranin II gene in PC12 cells (19, 63) . Here we found 2.3-fold increases in transfected secretogranin II promoter activity upon exposure to NGF or bFGF (Fig. 9A) , compared with 2.2-to 2.3-fold increments in endogenous gene expression (Fig. 3) . Promoter 5Ј deletion mutants indicated that these growth factor responses were retained up to Ϫ76 bp but were entirely lost by Ϫ40 bp (Fig. 9A) . This region contains the CRE. To test whether the CRE is sufficient to confer trophic factor responses, we transfected PC12 cells with pTKSgII-CRE-Luc (wild-type CRE) or pTK-SgII-⌬CRE-Luc (mutant CRE) plasmids. The CRE conferred 2.4-fold trophic factor responses onto the heterologous TK promoter, but a 75% decline in NGF or bFGF responses was noted for the CRE mutant construct (Fig. 9B) .
A 66% fall in NGF or bFGF stimulation occurred in the Ϫ76 bp promoter, compared with the Ϫ331 bp promoter (Fig. 9A) . This region contains the SRE. To test whether the SRE is sufficient to confer growth factor responses, we transfected PC12 cells with c-Fos-SRE-Luc (wild-type SRE) or c-Fos-⌬SRE-Luc (without a SRE). The c-Fos SRE conferred NGF or bFGF responses (by 1.7-to 2.2-fold), but the c-Fos promoter lacking an SRE lost 92-94% of the response to either NGF or bFGF (Fig. 9C) .
In comparing the relative potency (EC 50 values) and efficacy (maximal effect) of several secretagogues (nicotine, PACAP, NGF, or bFGF) to activate the transfected secretogranin II promoter (Table 1) , we found both the greatest potency (EC 50 ϭ 3.01 nm) and the greatest efficacy (4.93 luciferase light units/CAT dpm) for PACAP.
Discussion
The secretogranin II promoter is unique among chromogranin/secretogranin protein family members, in containing a SRE motif (Fig. 1) (25, 26) . The CRE and TATA regions are the only promoter domains common to chromogranin A, chromogranin B, and secretogranin II (33) . Previous reports have shown that the CRE region is crucial for neuroendocrine cell type-specific expression of mouse (33) and human (34) chromogranin A. The CRE plays critical roles for tissuespecific expression of the TH (64), neurotrophin-inducible vgf (65) , and ␣ 1B -adrenergic receptor genes (66) . For the well-studied chromogranin A promoter, a number of secre-FIG. 9. Effects of NGF or bFGF on the activity of secretogranin II promoter. A, Secretogranin II promoter progressive 5Ј deletion mutant/luciferase reporter plasmids were transfected, along with the transfection control efficiency plasmid, pRSV-CAT. Transfected cells were treated with either vehicle (control), NGF (100 ng/ml), or bFGF (20 ng/ml) for 24 h. Results are expressed as ratios of luciferase/CAT activities (n ϭ 6 transfections for each plasmid). *, P Ͻ 0.03. B, Stimulation of a heterologous (TK) promoter by the secretogranin II CRE site in response to NGF or bFGF. After transfection with synthetic CRE-TK luciferase constructs, PC12 cells were treated with NGF (100 ng/ml) or bFGF (20 ng/ml) for 24 h. Luciferase results were normalized to CAT activity (n ϭ 6 transfections for each plasmid). Secretogranin II CRE point mutations are indicated in bold and underlined type. *, P Ͻ 0.007. C, Role of the SRE in inducible gene expression by PC12 cells in response to NGF or bFGF. Synthetic c-Fos-SRE luciferase constructs were transfected into PC12 cells, which were treated with NGF (100 ng/ml) or bFGF (20 ng/ml) for 24 h. Luciferase results were normalized to CAT activity (n ϭ 6 transfections for each plasmid). *, P Ͻ 0.0001. tagogue responses also map onto the CRE box, including response to cAMP (33) , nicotinic cholinergic stimulation (36) , membrane depolarization (37) , protein kinase C activation (37) , NGF (38) , and the neuropeptide PACAP (39) . Do specific domains play similar roles in the secretogranin II promoter?
Northern blot analysis of steady-state secretogranin II mRNA revealed neuroendocrine expression in adrenomedullary [rat PC12 (Fig. 3) and mouse Path-2 ( Figs. 2 and 3) ], pituitary [AtT20 (mouse corticotrope), GC (rat somatotrope), and ␣T3-1 (mouse gonadotrope) (Fig. 2)] , and neuronal [Cath-a (mouse central TH-producing; Fig. 2 ) and GT1-7 (mouse GnRH-producing; Fig. 4) ] cells, but no expression was detected in control (NIH-3T3 fibroblast) cells (Fig. 2) . This is consistent with earlier observations that secretogranin II is expressed principally in endocrine cells and neurons (3) .
The transfected secretogranin II promoter also displayed cell type-specific expression (Fig. 5) , and a dramatic (95%) fall in secretogranin II promoter activity was noted upon deletion of the CRE region (Fig. 5) , suggesting that the CRE region at ([Ϫ67 bp] TGACGTCA [Ϫ60 bp]) is necessary for tissuespecific expression, much as in chromogranin A (33) . In addition, the CRE transfer experiments (Fig. 6A) suggest that the CRE region may be, at least partly, sufficient to confer tissue-specific expression in neuroendocrine cells.
Secretogranin II promoter 5Ј deletion mutants also revealed a substantial (48 -59%) decrease in promoter activity upon deletion of the SRE region ([Ϫ302 bp] GATGTCC [Ϫ296 bp]) (Fig. 5, A-D) , implicating the SRE, as well, in the tissuespecific expression of secretogranin II. A role for SRE elements in basal expression of several genes has been reported previously (67) (68) (69) . To ascertain more precisely the role of the SRE in tissue-specific expression, we transfected neuroendocrine (PC12 or AtT20) or control (NIH-3T3) cells with the c-Fos chimeric promoter plasmids (Fig. 6B) . Inclusion of an SRE in the c-Fos promoter resulted in 6.1-to 9.8-fold neuroendocrine expression, compared with that in control cells (Fig. 6B) . Such SRE domain transfers (Fig. 6B) suggest that the SRE may also be, at least partly, sufficient to account for the neuroendocrine tissue-specific expression of secretogranin II.
Tissue-specific elements for rat secretogranin II gene expression are yet to be identified (26) , but the 85% sequence homology between mouse and rat secretogranin II promoters (Fig. 1) suggests that the CRE and SRE will be important in both the mouse and rat. Recent reports revealed that a CRE cooperates with an E box (CANNTG) in directing neural cell-specific expression of the vgf gene (65) . It has also been reported that the CBP (CREB-binding protein) cooperates with the serum response factor for transactivation of the c-Fos SRE (70) . Because the c-Fos promoter, which contains CRE and SRE elements in similar orientation to the TATA box as that observed in the secretogranin II promoter, does not confer neuroendocrine cell type-specific expression onto c-Fos (68), it seems likely that other sequences and factors associated with the CRE and/or SRE in the secretogranin II gene provide unique information that confers neuroendocrine cell type specificity.
We also characterized promoter elements important to secretagogue-inducible expression of secretogranin II. Because the secretogranin II gene contains a CRE reported to be functional (32), we tested its regulation by the PKA pathway, using either the adenylyl cyclase stimulator forskolin or the PKA activator cAMP. Forskolin augmented secretogranin II expression in ␣T3-1 or GT1-7 cells (Fig. 4) . These findings are in agreement with results in bovine chromaffin cells (23) and neurons (24, 32) . Conflicting reports exist about regulation of secretogranin II expression by the PKA pathway in PC12 cells, including down-regulation by cAMP (32, 71) , or no change after cAMP (71) or forskolin (20) , with varying responses to cAMP in different PC12 subclones (71) . Our results in very-early-passage-number (passage numbers 12-25) PC12 cells (Figs. 3 and 7 ) are especially congruent with findings in bovine chromaffin cells (21) .
Catecholamine secretion from chromaffin cells is regulated by both cholinergic (acetylcholine released from splanchnic nerve) (56) and peptidergic (substance P, PACAP, and VIP also contained in the splanchnic nerve) (39, 60, 61, 72, 73) stimuli. Because secretogranin II is costored and cosecreted with catecholamines in response to such stimuli (3), we investigated whether cholinergic or peptidergic perturbations of secretion modify secretogranin II gene expression. Both nicotine and PACAP augmented secretogranin II expression (Figs. 3 and 8A ). An analogous result by nicotine was reported in bovine chromaffin cells (23) . Of note is the finding that PACAP seemed to be 33,223-fold more potent (3.01 nm vs. 100 m EC 50 values) and 5.2-fold more effective (maximal effect) than nicotine in activating secretogranin II expression (Table 1 ; Fig. 8A ), even though acetylcholine (acting at nicotinic cholinergic receptors) is usually recognized as the classical neurotransmitter controlling chromaffin cell responses. The reason for such high potency of PACAP remains unknown at this time, but the result is consistent with PACAP's action at a G protein-coupled receptor. PACAP is also a powerful activator of chromogranin A biosynthesis (39) .
Secretogranin II promoter 5Ј deletion mutants narrowed down the nicotinic and PACAP response elements to the proximal secretogranin II promoter, especially the CRE region (Fig. 8A) , suggesting the necessity of CRE in mediating these responses. CRE domain transfer to a heterologous TK promoter conferred responses to nicotine (by 2.3-fold) or PACAP (by 18.6-fold), indicating that CRE is also, at least 18.6 ng/ml 0.47 100 ng/ml bFGF 1.3 ng/ml 0.57 10 ng/ml PC12 cells were transfected with pXPC982 (982 bp secretogranin II promoter fused to luciferase reporter) plus pRSV-CAT (transfection efficiency control) and were treated for the next 24 h with log 10 -ascending doses of secretagogues or vehicle (mock). Cells were harvested at 24 h for measurement of luciferase and CAT. Results are expressed as luciferase/CAT ratios (minus mock). Efficacy was defined as maximal effect for any given secretagogue. Potency was defined as the concentration required to achieve 50% of maximal effect for any given secretagogue.
partly, sufficient to mediate these responses. The crucial involvement of the CRE element in mediating nicotinic and PACAP responses of the chromogranin A gene has been documented (36, 37, 39) .
We also documented involvement of the SRE in nicotinic and PACAP activation of secretogranin II gene expression (Fig. 8, A and C) . Our results with 5Ј deletions past the SRE revealed a substantial decrease in nicotine (74%) or PACAP (61%) responses (Fig. 8A) . The secretogranin II SRE is thus, at least partly, necessary to mediate the responses to nicotine or PACAP. In addition, SRE domain transfer to a neutral c-Fos promoter conferred responses to both nicotine (2.7-fold) and PACAP (8.3-fold), suggesting that this element is also, at least partly, sufficient to mediate responses to nicotine or PACAP. As in the secretogranin II gene, the SRE has also been implicated for basal and inducible expression of the atrial natriuretic factor gene (69) .
Because of the well-characterized effects of SRE elements in mediating multiple growth factor effects (19, 63, 74 -76) , we investigated the effects of NGF or bFGF on secretogranin II expression. A 2.3-fold increase in secretogranin II mRNA was noted after NGF or bFGF (Fig. 3) , in confirmation of previous findings (19) . Secretogranin II promoter 5Ј deletions past the CRE box abolished the trophin responses (Fig. 9A) , implicating the necessity of the CRE box. CRE domain transfer to a heterologous promoter also stimulated growth factor responses by 2.3-fold (Fig. 9B) , suggesting that the CRE is necessary for these responses. Substantial (ϳ66%) decrements in growth factor responses were noted after 5Ј promoter deletions past the SRE domain (Fig. 9A) , and transfer of the SRE domain to neutral c-Fos promoter conferred growth factor responses by 2-fold (Fig. 9C) . Thus, the SRE may, at least in part, play both necessary and sufficient roles in these responses.
In conclusion, the secretogranin II 5Ј flanking region is capable of conferring correct neuroendocrine cell type-specific expression onto the gene, as well as typical secretagogue responses. Both basal expression and secretagogue inducibility are localized to the proximal promoter. The proximal CRE box, at [Ϫ67 bp] TGACGTCA [Ϫ60 bp], seems to be the most crucial element in mediating these responses; whereas the SRE motif, at [Ϫ302 bp] GATGTCC [Ϫ296 bp], also has a substantial role in both responses.
